Today: 6 November 2025
Subscribe
Browse Category

Stock Market News News 11 October 2025 - 16 October 2025

Zions Bancorp Stock Plunges 13% After Surprise $50M Fraud-Linked Loan Loss – Is More Trouble Ahead?

Zions Bancorp Stock Plunges 13% After Surprise $50M Fraud-Linked Loan Loss – Is More Trouble Ahead?

Fraudulent Loan Bombshell Hits Zions’ Books Zions Bancorporation shocked the market this week by revealing a significant credit mishap at its California division. In a late Wednesday 8-K filing, the Salt Lake City-based regional bank disclosed it discovered potential fraud in two related commercial loans totaling about $60 million investing.com. After an internal review unearthed “misrepresentations and irregularities” by the borrowers, Zions decided to write off $50 million of the loans and take a provision for the rest, effectively recognizing a total $60 million exposure as likely lost investing.com. The bank has already accelerated the loans to default and filed
16 October 2025
 ·  ·  ·  ·  ·  · 
Recursion (RXRX) Stock Surges on AI-Driven Breakthroughs and Big-Pharma Deals

Recursion (RXRX) Stock Surges on AI-Driven Breakthroughs and Big-Pharma Deals

Recursion Pharmaceuticals (NASDAQ: RXRX) is a Salt Lake City–based clinical-stage “TechBio” biotech that uses AI, automation and massive biological datasets to speed drug discovery ts2.tech. In early October 2025 the stock showed wild swings: it plunged to the mid-$5s then rebounded ~16% on Oct 8 after an AI-focused tech conference and pipeline news ts2.tech ts2.tech. As of mid-day Oct 16, RXRX trades around $6.5, having closed at ~$6.79 on Oct 16 insidermonkey.com. This volatility reflects renewed investor interest in Recursion’s AI platform and upcoming trial readouts. Key Facts Recent Stock Performance Recursion’s share price has been unusually volatile in October
16 October 2025
 ·  ·  ·  ·  · 
Kelly Services’ Tech-Driven Hiring Triumphs Spark Stock Rally Hopes

Kelly Services’ Tech-Driven Hiring Triumphs Spark Stock Rally Hopes

Double Honors in Staffing Leadership Kelly Services has grabbed headlines by earning dual top honors from leading industry analyst Everest Group. In the newly released 2025 U.S. Contingent Staffing PEAK Matrix assessments, Kelly was designated both a Leader and a Star Performer, recognizing its superior capabilities and momentum in supplying talent. Notably, Kelly achieved this in both the professional/administrative and industrial staffing categories, marking “the first time any firm” has ever swept both distinctions across all evaluated segments ts2.tech. This unprecedented feat underscores how far the 77-year-old staffing giant has evolved beyond traditional temp services into a tech-savvy talent solutions
16 October 2025
 ·  ·  ·  ·  · 
Travelers Companies (TRV) Q3 Earnings Blow Past Estimates as Catastrophe Losses Tumble – Analysts Weigh In

Travelers Companies (TRV) Q3 Earnings Blow Past Estimates as Catastrophe Losses Tumble – Analysts Weigh In

Stellar Q3 Lifts Earnings – Stock Reaction Travelers’ Q3 earnings report (released Oct. 16 before markets) showed robust profitability and low catastrophe losses. Core income jumped to $8.14 per diluted share reuters.com, crushing prior-year ($5.24) and analyst forecasts benzinga.com. Net income was ~$1.888B (≈$8.24/sh), up ~52% from 2024, on revenues of $12.47B (above forecasts) tokenist.com. Underwriting gains more than doubled year-over-year, helped by a swing in catastrophe costs (only $402M vs $939M prior year) reuters.com gurufocus.com. The combined ratio (losses plus expenses / premiums) was a very strong 87–84% range reuters.com gurufocus.com. Early trading on Oct. 16 saw the stock
16 October 2025
 ·  ·  ·  ·  · 
Sonder Holdings (SOND) Stock Skyrockets 50% After Q2 Earnings and New Partnership Surprise

Sonder Holdings (SOND) Stock Skyrockets 50% After Q2 Earnings and New Partnership Surprise

Stock Rebound After Hitting Record Lows Sonder’s stock price is on a rollercoaster this week. On Wednesday, Oct. 15, SOND closed at $0.92, down nearly 4% for the day and extending a multi-day slump marketbeat.com. In fact, shares had crumbled about 20% just in the past week and nearly 45% over the past month marketscreener.com, touching historic lows around $0.95. This precipitous decline has wiped out 75% of Sonder’s market value in the last year finviz.com, and astonishingly, the stock now sits 97% below its levels of three years ago finviz.com (when the company went public via SPAC in 2021).
16 October 2025
 ·  ·  ·  ·  · 
Uranium Royalty Stock Soars on Nuclear Boom – UROY Hits New High, What’s Next?

Uranium Royalty Stock Soars on Nuclear Boom – UROY Hits New High, What’s Next?

UROY Stock Blasts Off Amid Uranium Market Revival Uranium Royalty Corp’s stock price has been on a tear, riding a wave of optimism in the nuclear energy sector. On October 15, UROY spiked intraday to about $4.87 per share, its highest level in a year marketbeat.com. It closed that session up over 11% at roughly $4.75 finviz.com – capping a stunning rally in recent months. Just a year ago UROY traded near $2.50; it has since doubled in value, now sitting ~85% higher than 12 months prior finviz.com. Over 116% of those gains have come in 2025 alone as the
16 October 2025
 ·  ·  ·  ·  · 
Shocking CFO Departure Sends BDX Stock Tumbling — But Growth Remains Strong

Shocking CFO Departure Sends BDX Stock Tumbling — But Growth Remains Strong

Leadership Change and Growth: BD’s CFO Chris DelOrefice surprised the market by resigning in mid-October prnewswire.com. According to the official release, DelOrefice is pursuing an outside opportunity, and Roque will cover the CFO role through the transition. Polen emphasized DelOrefice’s contributions to BD’s strategic overhaul and said Roque — a 20-year finance veteran at BD — is “well positioned” to keep executing the company’s plans prnewswire.com reuters.com. The leadership news coincided with a positive earnings update: BD reported that Q4 sales hit $5.89 billion (a +8.3% increase) finimize.com and full-year revenue about $21.8 billion. On a constant-currency, organic basis growth was more
16 October 2025
 ·  ·  ·  ·  · 
Lockheed Martin News Roundup (Oct 1–10, 2025): Defense Giant Navigates New Contracts, Space Ambitions, and Market Momentum

Lockheed Martin (LMT) Stock Rises on $11B Navy Contract, Dividend Hike & Analyst Upgrades

Stock Performance Today and Recent Trend Lockheed’s stock opened around $504.8 on Oct. 15, 2025 and is roughly flat on the day marketbeat.com. Over the past week it has seen minor fluctuation but remains in a broad trading range. After falling as low as ~$410 in mid-July (post-Q2 earnings), LMT has rebounded over 20% and is now about 18% below its 52-week high benzinga.com marketbeat.com. Volume remains healthy and trading above its 50-day/200-day averages, reflecting continued investor interest. Despite some recent volatility, analysts note that LMT has strong governmental support. “Lockheed Martin makes 97% of its revenue from the U.S.
15 October 2025
 ·  ·  ·  ·  · 
Astera Labs (ALAB) Stock Plummets After AMD-Oracle AI Deal – What Investors Should Know

Astera Labs (ALAB) Stock Plummets After AMD-Oracle AI Deal – What Investors Should Know

Astera’s stock has been volatile on recent AI infrastructure news. After surging on an earlier AMD/OpenAI deal – Citi analysts noted Astera’s shares “popped 10%” after that announcement investopedia.com – the Oct 14 AMD-Oracle GPU deal triggered a sharp pullback tipranks.com. The sell-off reflects renewed competition concerns: Morgan Stanley warned Nvidia’s NVLink could eventually “replace the traditional PCIe connection” between CPU and GPU, directly threatening Astera’s core business gurufocus.com. Astera has countered by stressing open standards. Analyst Patrick Moorhead (Moor Insights) observes that “open standards are critical” for next-generation AI rack architectures nasdaq.com, while Astera’s CEO Sanjay Gajendra emphasizes the
15 October 2025
 ·  ·  ·  ·  · 
Aqua Metals (AQMS) Set to Explode on Battery-Recycling Breakthroughs? Insider Report Shakes EV Supply Chains

Aqua Metals (AQMS) Set to Explode on Battery-Recycling Breakthroughs? Insider Report Shakes EV Supply Chains

Business Model & Strategy Aqua Metals is an early‑stage recycling technology company. It developed AquaRefining originally for lead batteries and is now focusing on lithium‑ion battery recycling. The company’s strategy is to build and operate recycling facilities (like its “Sierra ARC” campus) and to license its proprietary systems to others. AquaRefining uses modular units that run at room temperature using electricity and aqueous chemistry 6kinc.com sustainablebusinessmagazine.net. This avoids the high heat and polluting chemicals of conventional smelting. In Aqua Metals’ own words, it has a “commercially proven sustainable, closed‑loop metal recycling process” capable of yielding the purest metals aquametals.com. The
14 October 2025
 ·  ·  ·  ·  · 
Navitas Semiconductor (NVTS) Stock Skyrockets 27% on Nvidia AI Breakthrough – Is a Major Rally Just Beginning?

Navitas Semiconductor (NVTS) Stock Skyrockets 27% on Nvidia AI Breakthrough – Is a Major Rally Just Beginning?

In-Depth Analysis: Navitas Semiconductor (NVTS) is a fabless chipmaker (founded 2014) specializing in wide-bandgap power electronics. It pioneered “GaNFast” ICs that monolithically integrate GaN transistors with control circuits ts2.tech. These allow much smaller, more efficient power supplies (e.g. fast chargers) because GaN can run at higher frequencies with lower losses. In 2022 the company also acquired GeneSiC, adding high-voltage SiC diodes and MOSFETs for EV and energy applications. By mid-2025, Navitas’ revenue mix was split among fast chargers (for phones/laptops), industrial, solar, EV, and (latest) data centers finviz.com ts2.tech. However, growth stalled in 2024–25. Navitas had warned that mobile/consumer demand
14 October 2025
 ·  ·  ·  ·  · 
NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

Company Overview: History & Mission NewAmsterdam Pharma Company N.V. is a Netherlands-based biotech (with U.S. operations in Miami) on a mission to “change the landscape of lipid-lowering treatment” for cardiovascular disease newamsterdampharma.com. Founded in early 2020, the company sprang from the vision of Prof. John J.P. Kastelein – a world-renowned expert in lipid disorders – and venture capital firm Forbion newamsterdampharma.com. They acquired the rights to obicetrapib, a once-abandoned CETP inhibitor, from an Amgen subsidiary in 2020 newamsterdampharma.com. Soon after, Dr. Michael Davidson (a leading preventive cardiologist) joined as co-founder and CEO, bringing deep clinical expertise to the leadership team
11 October 2025
 ·  ·  ·  ·  · 
1 2 3
Go toTop